Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315692 · ClinicalTrials.gov registry record
Risk of Ovarian Cancer in Patients With a Pelvic Mass
A clinical trial of Ovarian Cancer, sponsored by Fujirebio Diagnostics.
- Completed
- Registry status
- 566
- Enrollment target
- 2
- Study locations
NCT00315692: Completed study of Ovarian Cancer, sponsored by Fujirebio Diagnostics.
NCT00315692 is a study of Ovarian Cancer that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 566 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (22% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315692, a study of Ovarian Cancer, has completed, sponsored by Fujirebio Diagnostics.
- COMPLETED
- Registry status
- 566 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this clinical trial is to evaluate the ability of multiple serum biomarkers to estimate the risk of ovarian cancer in women presenting with pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass).
Conditions Studied
Interventions
- DEVICE Biomarker Assay (CA125 and HE4)
Study Locations (2)
Pennsylvania
- Fujirebio Diagnostics, Inc - Malvern
Rhode Island
- Richard Moore - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 566 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-02 |
What the finished NCT00315692 record still lists
NCT00315692 is an observational study that tracks outcomes without assigning an intervention. The registered 566 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biomarker Assay (CA125 and HE4) is the first listed.
NCT00315692 reports a single indexed study location in Pennsylvania, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00315692 about?
NCT00315692 is a clinical study titled "Risk of Ovarian Cancer in Patients With a Pelvic Mass". The purpose of this clinical trial is to evaluate the ability of multiple serum biomarkers to estimate the risk of ovarian cancer in women presenting with pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass).
What is the current status of trial NCT00315692?
This trial is currently completed. The enrollment target is 566 participants. The study started on 2005-12. Estimated completion is 2007-02.
What conditions does trial NCT00315692 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT00315692?
The interventions under investigation include: Biomarker Assay (CA125 and HE4) (DEVICE).
Who is sponsoring clinical trial NCT00315692?
This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315692 being conducted?
This trial has 2 study locations across Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00315692's enrollment target sits among peer trials
566 41st of 322 higher than 281 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05472441 · 568 participants · NA
Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia